These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23409931)

  • 21. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.
    Kam YW; Lum FM; Teo TH; Lee WW; Simarmata D; Harjanto S; Chua CL; Chan YF; Wee JK; Chow A; Lin RT; Leo YS; Le Grand R; Sam IC; Tong JC; Roques P; Wiesmüller KH; Rénia L; Rötzschke O; Ng LF
    EMBO Mol Med; 2012 Apr; 4(4):330-43. PubMed ID: 22389221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective chikungunya virus-like particle vaccine produced in insect cells.
    Metz SW; Gardner J; Geertsema C; Le TT; Goh L; Vlak JM; Suhrbier A; Pijlman GP
    PLoS Negl Trop Dis; 2013; 7(3):e2124. PubMed ID: 23516657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mapping of Chikungunya virus interactions with host proteins identified nsP2 as a highly connected viral component.
    Bouraï M; Lucas-Hourani M; Gad HH; Drosten C; Jacob Y; Tafforeau L; Cassonnet P; Jones LM; Judith D; Couderc T; Lecuit M; André P; Kümmerer BM; Lotteau V; Desprès P; Tangy F; Vidalain PO
    J Virol; 2012 Mar; 86(6):3121-34. PubMed ID: 22258240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chikungunya virus infection disrupts MHC-I antigen presentation via nonstructural protein 2.
    Ware BC; Parks MG; da Silva MOL; Morrison TE
    PLoS Pathog; 2024 Mar; 20(3):e1011794. PubMed ID: 38483968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection.
    Akahata W; Yang ZY; Andersen H; Sun S; Holdaway HA; Kong WP; Lewis MG; Higgs S; Rossmann MG; Rao S; Nabel GJ
    Nat Med; 2010 Mar; 16(3):334-8. PubMed ID: 20111039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice.
    Piper A; Ribeiro M; Smith KM; Briggs CM; Huitt E; Nanda K; Spears CJ; Quiles M; Cullen J; Thomas ME; Brown DT; Hernandez R
    J Virol; 2013 Jun; 87(12):6748-57. PubMed ID: 23552427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. G3BP/Rin-Binding Motifs Inserted into Flexible Regions of nsP2 Support RNA Replication of Chikungunya Virus.
    Wang S; Merits A
    J Virol; 2022 Nov; 96(21):e0127822. PubMed ID: 36226983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection.
    Kishishita N; Takeda N; Anuegoonpipat A; Anantapreecha S
    J Clin Microbiol; 2013 May; 51(5):1389-95. PubMed ID: 23408687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
    Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
    Front Immunol; 2020; 11():304. PubMed ID: 32194557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of neutralizing antibodies produced by papaya mosaic virus nanoparticles fused to the E2EP3 peptide epitope of Chikungunya envelope.
    Nor Rashid N; Teoh TC; Al-Harbi SJ; Yusof R; Rothan HA
    Trop Biomed; 2021 Mar; 38(1):36-41. PubMed ID: 33797522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.
    Warter L; Lee CY; Thiagarajan R; Grandadam M; Lebecque S; Lin RT; Bertin-Maghit S; Ng LF; Abastado JP; Desprès P; Wang CI; Nardin A
    J Immunol; 2011 Mar; 186(5):3258-64. PubMed ID: 21278338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response.
    Olagnier D; Scholte FE; Chiang C; Albulescu IC; Nichols C; He Z; Lin R; Snijder EJ; van Hemert MJ; Hiscott J
    J Virol; 2014 Apr; 88(8):4180-94. PubMed ID: 24478443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chikungunya Virus nsP2 Impairs MDA5/RIG-I-Mediated Induction of NF-κB Promoter Activation: A Potential Target for Virus-Specific Therapeutics.
    Bae S; Lee JY; Myoung J
    J Microbiol Biotechnol; 2020 Dec; 30(12):1801-1809. PubMed ID: 33323678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chikungunya virus and prospects for a vaccine.
    Weaver SC; Osorio JE; Livengood JA; Chen R; Stinchcomb DT
    Expert Rev Vaccines; 2012 Sep; 11(9):1087-101. PubMed ID: 23151166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine.
    Partidos CD; Paykel J; Weger J; Borland EM; Powers AM; Seymour R; Weaver SC; Stinchcomb DT; Osorio JE
    Vaccine; 2012 Jun; 30(31):4638-43. PubMed ID: 22583812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P38 and JNK Mitogen-Activated Protein Kinases Interact With Chikungunya Virus Non-structural Protein-2 and Regulate TNF Induction During Viral Infection in Macrophages.
    Nayak TK; Mamidi P; Sahoo SS; Kumar PS; Mahish C; Chatterjee S; Subudhi BB; Chattopadhyay S; Chattopadhyay S
    Front Immunol; 2019; 10():786. PubMed ID: 31031770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations conferring a noncytotoxic phenotype on chikungunya virus replicons compromise enzymatic properties of nonstructural protein 2.
    Utt A; Das PK; Varjak M; Lulla V; Lulla A; Merits A
    J Virol; 2015 Mar; 89(6):3145-62. PubMed ID: 25552719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.
    Zhang YN; Deng CL; Li JQ; Li N; Zhang QY; Ye HQ; Yuan ZM; Zhang B
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Chikungunya virus early replication by intracellular nanoantibodies targeting nsP2 Epitope Rich Region.
    Deng Q; Guo Z; Hu H; Li Q; Zhang Y; Wang J; Liao C; Guo C; Li X; Chen Z; Lu J
    Antiviral Res; 2022 Dec; 208():105446. PubMed ID: 36270543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and evaluation of Chikungunya virus E1 and E2 envelope proteins for serodiagnosis of Chikungunya virus infection.
    Cho B; Jeon BY; Kim J; Noh J; Kim J; Park M; Park S
    Yonsei Med J; 2008 Oct; 49(5):828-35. PubMed ID: 18972604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.